Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), ... Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets. Mehr anzeigen
手足口病に対する多価ワクチンの第III相臨床試験は世界で初めての試みとなる （ビジネスワイヤ） -- 中国のバイオ医薬品におけるリーディングプロバイダーであるシノバック・バイオテック（ 「シノバック」...
Die weltweit erste klinische Phase-III-Studie zu einem multivalenten HFMD-Impfstoff Sinovac Biotech Ltd. („SINOVAC“ oder das „Unternehmen“) (NASDAQ: SVA), ein führender Anbieter von...
Le premier essai clinique de Phase III au monde sur un vaccin multivalent contre la MMPB Sinovac Biotech Ltd. (« SINOVAC » ou la « Société ») (NASDAQ : SVA), l'un des principaux fournisseurs de...
The first phase III clinical trial on a multivalent HFMD vaccine in the world Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 4 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 12 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 26 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 52 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 156 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| 260 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
